Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02314793
Recruitment Status : Terminated (The study has been terminated because of operational reasons.)
First Posted : December 11, 2014
Last Update Posted : June 21, 2016
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP2205 in healthy young male and female subjects. This study will also evaluate the safety and tolerability of multiple ascending oral doses of ASP2205 in healthy young and elderly female subjects.

Condition or disease Intervention/treatment Phase
Healthy Subjects Pharmacokinetics of ASP2205 Drug: ASP2205 Drug: Placebo Phase 1

Detailed Description:

Part 1 is a single ascending dose investigator-blinded study in healthy young male and female subjects. Six doses of ASP2205 or matching placebo will be given to separate cohorts consisting of 8 subjects each, with 6 subjects receiving ASP2205 and 2 subjects receiving matching placebo. ASP2205 or matching placebo will be given as a single oral dose under fasted conditions.

The effect of a high-calorie high-fat meal (breakfast) on the safety, tolerability and pharmacokinetics of a single oral dose of ASP2205 will be evaluated in a separate cohort of 8 subjects in an open-label manner.

Part 2 is a multiple ascending dose subject- and investigator-blinded study comprising 3 cohorts with each 12 healthy young (aged 25 to 55 years) female subjects and 1 cohort with 12 healthy elderly (aged 65 years or older) female subjects who will receive ASP2205 or matching placebo. Nine subjects in each cohort will be treated with ASP2205 and 3 subjects will be treated with matching placebo (ratio 3:1).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205
Study Start Date : November 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Arm Intervention/treatment
Experimental: Part 1: Single Ascending Dose ASP2205 (Fasting)
Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
Drug: ASP2205
oral

Placebo Comparator: Part 1: Single Ascending Dose Placebo (Fasting)
Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
Drug: Placebo
oral

Experimental: Part 1: Single Ascending Dose ASP2205 (Fed)
Young male and female subjects will receive a single dose of ASP2205
Drug: ASP2205
oral

Experimental: Part 2: Multiple Ascending Dose ASP2205, Young females
Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
Drug: ASP2205
oral

Placebo Comparator: Part 2: Multiple Ascending Dose Placebo, Young females
Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
Drug: Placebo
oral

Experimental: Part 2: Multiple Ascending Dose ASP2205, Elderly females
Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
Drug: ASP2205
oral

Placebo Comparator: Part 2: Multiple Ascending Dose Placebo, Elderly females
Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
Drug: Placebo
oral




Primary Outcome Measures :
  1. Part 1 and Part 2: Safety assessed by nature, frequency and severity of adverse events [ Time Frame: up to 29 days ]
  2. Part 1 and Part 2: Safety assessed by vital signs [ Time Frame: up to 29 days ]
    Vital signs include blood pressure, pulse rate, body temperature

  3. Part 1 and Part 2: Safety assessed by orthostatic challenge test [ Time Frame: up to 29 days ]
  4. Part 1 and Part 2: Assessment of clinical laboratory tests [ Time Frame: up to 29 days ]
    Clinical laboratory tests include hematology, biochemistry and urinalysis

  5. Part 1 and Part 2: Safety assessed by routine 12 lead electrocardiogram (ECG) [ Time Frame: up to 29 days ]
  6. Part 1 and Part 2: Safety assessed by continuous cardiac monitoring (Holter ECG) [ Time Frame: up to 29 days ]
  7. Part 1: Safety assessed by real-time cardiac monitoring (ECG telemetry) [ Time Frame: up to 16 days ]

Secondary Outcome Measures :
  1. Part 1 and Part 2: Safety laboratory test: prolactin [ Time Frame: up to 29 days ]
  2. Part 1 and Part 2: Safety laboratory test: cortisol [ Time Frame: up to 29 days ]
  3. Part 1 and Part 2: Safety laboratory test: bicarbonate (HCO3) [ Time Frame: up to 29 days ]
  4. Part 1 and Part 2: Safety assessed by chemistry profile [ Time Frame: up to 29 days ]
    Chemistry profile includes total cholesterol, high-density lipoprotein (HDL) / low-density lipoprotein (LDL), triglycerides

  5. Part 1 and Part 2: Safety laboratory test: fasting blood glucose [ Time Frame: up to 29 days ]
  6. Part 1 and Part 2: Safety laboratory test: creatinine urine [ Time Frame: up to 29 days ]
  7. Part 1: Central nervous system (CNS) safety monitoring: Bond & Lader visual analogue scale (VAS) [ Time Frame: up to 4 days ]
  8. Part 1: CNS safety monitoring: Drug effects questionnaire (DEQ) VAS [ Time Frame: up to 4 days ]
    PhenX toolkit version

  9. Part 1: Pharmacokinetics profile of ASP2205 in plasma: AUCinf, AUCinf (% extrapolated), AUClast, AUC24, CL/F, Cmax, terminal elimination rate constant, MRT, tlag, tmax, t1/2, Vz/F [ Time Frame: Day 1 ]
    Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf), percentage of AUCinf due to extrapolation from tlast to time infinity (AUCinf %extrapolated), AUC from the time of dosing to the last measurable concentration (AUClast), AUC from the time of dosing to 24 hours (AUC24), apparent total systemic clearance after single or multiple extravascular dosing (CL/F), maximum concentration (Cmax), mean residence time (MRT), time prior to the time corresponding to the first measurable (nonzero) concentration (tlag), time to maximum concentration (tmax), terminal elimination half-life (t1/2), apparent volume of distribution during the terminal elimination phase after single or multiple extravascular dosing (Vz/F)

  10. Part 1: Pharmacokinetics profile of ASP2205 in urine: Aeinf, Aeinf%, Aelast, Aelast%, CLR [ Time Frame: Day 1 ]
    Cumulative amount of drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf), percentage of drug dose excreted into urine from time of dosing extrapolated to time infinity (Aeinf%), cumulative amount of drug excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast), percentage of drug dose excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast%), renal clearance (CLR)

  11. Part 2: Safety laboratory test: di-docosahexaenoyl-bis(monoacylglycerol) phosphate (di-22:6-BMP) in serum and urine [ Time Frame: up to 29 days ]
  12. Part 2: CNS safety monitoring: CogState's neurocognition test battery (short version) [ Time Frame: up to 14 days ]
  13. Part 2: CNS safety monitoring: Bond & Lader VAS [ Time Frame: up to 17 days ]
  14. Part 2: CNS safety monitoring: DEQ VAS [ Time Frame: Time Frame : up to 13 days ]
    PhenX toolkit version

  15. Part 2: CNS safety monitoring: Addiction Research Center Inventory (49-item short form) (ARCI-49) [ Time Frame: up to 13 days ]
  16. Part 2: CNS safety monitoring: Physician Withdrawal Checklist [ Time Frame: up to 29 days ]
  17. Part 2: CNS safety monitoring: Columbia - Suicide Severity Rate Scale (C-SSRS) [ Time Frame: up to 29 days ]
  18. Part 2: Appetite visual analogue scale (AVAS) [ Time Frame: up to 15 days ]
  19. Part 2: Nausea VAS [ Time Frame: up to 15 days ]
    From the McGill Nausea questionnaire

  20. Part 2: Body weight [ Time Frame: up to 29 days ]
  21. Part 2: Total daily urine production (24-hour volume) [ Time Frame: up to 15 days ]
  22. Part 2: Total daily urine osmolality (24 hour pooled sample from each void) [ Time Frame: up to 15 days ]
  23. Part 2: Total daily fluid intake [ Time Frame: up to 15 days ]
  24. Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUC24, Cmax, tlag, tmax [ Time Frame: Day 1 ]
  25. Part 2: Pharmacokinetic parameter: Ctrough [ Time Frame: Day 1 immediately prior to dosing (morning Ctrough and, only in case of twice daily dosing, evening C trough): days 2, 4, 6, 8, 10, 12 ]
  26. Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUCtau, Cmax, tmax [ Time Frame: Days 12, 13 (in case of twice daily dosing) ]
  27. Part 2: Pharmacokinetic profile of ASP2205 in plasma: AUCtau, CL/F, Cmax, terminal elimination rate constant, MRT, peak trough ratio (PTR), accumulation ratio calculated using the area under the concentration -time curve [Rac(AUC)], tmax, t1/2, VzF [ Time Frame: Day 14 ]
  28. Part 2: Pharmacokinetic profile of ASP2205 in urine: Aetau, Aetau%, CLR [ Time Frame: Day 14 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject is a healthy young male or female subject aged 25 to 55 years, inclusive, at screening (part 1 and 2) or healthy elderly female subject aged ≥ 65 years, inclusive, at screening (part 2 only).
  • Subject has a body mass index (BMI) range of 18.5 - 30.0 kg/m2, inclusive. The subject weighs at least 50 kg (at screening).
  • Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria:

  • Female subject who has been pregnant within 6 months prior to screening assessment or breastfeeding within 3 months prior to screening.
  • Subject has a known or suspected hypersensitivity to ASP2205 or any components of the formulations used.
  • Subject has any of the liver function tests (LTs; aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase (ALP), gamma glutamyl transferase, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case, the assessment may be repeated once (admission to the clinical unit).
  • Subject has at screening any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies).
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic (including surgical procedures to treat pelvic trauma), pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (noncutaneous) infection within 1 week prior to admission to the clinical unit.
  • Subject has a relevant history of attempted suicide or suicidal behavior. Any recent suicidal ideation within the last 6 months or who are at significant risk to commit suicide.
  • Subject has any clinically significant abnormality.
  • Subject has a mean pulse < 40 or > 90 bpm; mean systolic blood pressure (SBP) > 140 mmHg; mean DBP > 90 mmHg (elderly subjects: mean SBP > 160 mmHg; mean DBP > 100 mmHg) (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse will be measured automatically) prior to the admission to the clinical unit (triplicates taken at screening and on admission to the clinical unit). If the mean blood pressure exceeds the limits above, 1 additional triplicate can be taken.
  • Subject has a mean corrected QT interval using Fridericia's formula (QTcF) > 430 ms (for male subjects) and > 450 ms (for female subjects) at admission to the clinical unit. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken.
  • Subject uses any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day) and except for use of contraceptives or hormone replacement therapy.
  • Subject has a history of smoking within 6 months prior to admission to the clinical unit.
  • Subject has a history of drinking > 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) (> 14 units of alcohol for female subjects) within 3 months prior to admission to the clinical unit.
  • Subject uses grapefruit juice (more than 3 × 200 mL) or products containing grapefruit and/or Seville oranges (more than 3 times) in the week prior to admission to the clinical unit until ESV, as reported by the subject.
  • Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject regularly uses any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
  • Subject had significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to admission to the clinical unit.
  • Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis A virus antibodies (immunoglobulin M) (anti-HAV [IgM]), hepatitis C virus antibodies (anti-HCV) or antibodies to human immunodeficiency virus type 1 (HIV-1) and/or type 2 (HIV-2) at screening.
  • Subject has been treated with any investigational drugs within 90 days or 5 terminal half-lives, whichever is longer, prior to drug administration.
  • Subject is unable to communicate, read and understand English, or has any other condition which makes the subject unsuitable for study participation.
  • Subject is an employee of the Astellas Group or Clinical Research Organization involved in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02314793


Locations
Layout table for location information
United Kingdom
Site GB44001
Harrow, United Kingdom, HA1 3UJ
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Layout table for investigator information
Study Director: Associate Medical Director Astellas Pharma Europe B.V.

Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02314793     History of Changes
Other Study ID Numbers: 2205-CL-0001
2014-003059-71 ( EudraCT Number )
First Posted: December 11, 2014    Key Record Dates
Last Update Posted: June 21, 2016
Last Verified: June 2016

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
Pharmacokinetics
ASP2205